Overview

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
This study will determine the appropriate dose and frequency of administration of sc Mircera maintenance therapy in dialysis patients with chronic renal anemia who were previously receiving sc epoetin alfa or beta. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Epoetin Alfa